Trials / Completed
CompletedNCT00912964
A Study to Test the Efficacy and Safety of the Beta-3 Agonist Mirabegron (YM178) in Patients With Symptoms of Overactive Bladder
A Phase III, Randomized, Double-Blind, Parallel Group, Placebo Controlled, Multicenter Study to Assess the Efficacy and Safety of the Beta-3 Agonist Mirabegron (25 mg qd and 50 mg qd) in Subjects With Symptoms of Overactive Bladder
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2,030 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The study is intended to test efficacy, safety and tolerability of two doses of once daily (qd) Mirabegron against placebo to treat patients with symptoms of overactive bladder.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Mirabegron | Mirabegron tablets |
| DRUG | Placebo | Matching mirabegron placebo tablets. |
Timeline
- Start date
- 2009-04-28
- Primary completion
- 2010-04-27
- Completion
- 2010-04-27
- First posted
- 2009-06-03
- Last updated
- 2024-11-21
- Results posted
- 2012-10-17
Locations
151 sites across 11 countries: United States, Canada, Czechia, Denmark, Finland, Germany, Hungary, Norway, Slovakia, Spain, Sweden
Source: ClinicalTrials.gov record NCT00912964. Inclusion in this directory is not an endorsement.